Developed by Monaghan Medical, the AEROVERSE® system of care is a precision engineered collection of respiratory therapy devices designed with intent to deliver clinical efficiency, versatility, and improved patient outcomes. Built with the specific needs of clinicians and patients in mind, this integrated platform connects three essential devices: the AEROBIKA® Oscillatory Positive Expiratory Pressure (OPEP) device, the AEROECLIPSE® BAN® Nebulizers, and the VERSAPAP® Positive Airway Pressure (PAP) device.
A Fully Integrated Therapeutic Solution for Respiratory Care
The AEROVERSE® system provides eight unique therapeutic options that can be tailored to meet the clinical goals of a wide range of respiratory conditions. Each device can be used individually or connect with the other AEROVERSE® System products – no adapters required. This streamlines clinical workflows, and most importantly, combining devices does not compromise the performance or outcomes of individual treatments.
All eight device configurations in this system have been tested and are FDA 510(k) cleared as safe and effective for their intended uses. The complete system of care is available in many acute care facilities, and all but the VERSAPAP® device are available outside the hospital to authorized distributors and durable medical equipment (DME) providers in most markets. Patients can also transition from hospital to home using compatible devices, such as the AEROECLIPSE® XL R BAN with an OMBRA® compressor, helping provide continuity and efficiency without the need for additional equipment.
Clinical Benefits of the AEROBIKA® OPEP Device in COPD and Chronic Lung Disease
The AEROBIKA® OPEP device is a tool for managing chronic respiratory conditions. By generating oscillations and positive expiratory pressure, the AEROBIKA® OPEP device can open weak or collapsed airways allowing the oscillations to facilitate mucus movement to the upper airway for easier clearance.
Clinical research supports use of the AEROBIKA® OPEP device to improve mucus clearance, reduce coughing and breathlessness, and increase exercise tolerance. These benefits can contribute to a better quality of life and are supported by imaging studies showing improved lung ventilation after short-term use. These physiological benefits are echoed in real-world studies showing:
- 28% reduction in moderate-to-severe COPD exacerbations
- 39% reduction in post-operative all-cause readmissions
While other OPEP devices are available on the market, functional characteristics such as expiratory pressure, oscillation depth, and flow velocity vary significantly among them. These differences matter, as they can affect patient response and therapeutic efficacy.
Additionally, the AEROBIKA® OPEP device is available with a manometer accessory. This does not change the underlying functionality of the device alone, but it does offer some added benefits. The red, yellow and green zones on the manometer provide visual feedback of exhalation technique on a breath-to-breath basis to help users reach the proper pressures (green zone) to maximize therapeutic results. It can also be helpful in determining and optimizing the resistance settings.
AEROECLIPSE® Breath Actuated Nebulizer: Efficient Drug Delivery for Respiratory Patients
There are two versions of the AEROECLIPSE® BAN® Nebulizers. The AEROECLIPSE® II BAN® Nebulizer is a 7-day disposable device most often used in acute care or hospital settings. Whereas the AEROECLIPSE® XL R BAN® can be disinfected and re-used for a 6-month life span to serve people with chronic pulmonary conditions like bronchiectasis or COPD.
The BAN® Nebulizers represent a major advancement in medication delivery. Unlike traditional jet nebulizers that produce aerosol continuously—even during exhalation or patient pauses—the AEROECLIPSE® BAN® Nebulizers produce aerosol only when the patient inhales. This breath-actuated mechanism may reduce medication waste, minimize environmental exposure for clinicians, and support safer workplace conditions.
A scintigraphy study demonstrates that this device delivers 75% of medication into the lungs, compared to less than 50% with constant-output nebulizers. By delivering medication exactly where it’s needed – deep in the lungs – it can help better manage chronic respiratory conditions, while lowering the risk of side effects caused by upper airway deposition.
Critically, the AEROECLIPSE® BAN® Nebulizers deliver consistent, high respirable doses regardless of a patient’s breathing pattern – a key advantage over standard jet nebulizers, which may be less efficient and might lose performance with use and prolonged exhalation times. This makes it especially valuable in emergency departments, where fast, effective treatment is essential.
Additionally, its design helps reduce unintended aerosol exposure for healthcare workers. A study conducted in an emergency department found that implementation of the AEROECLIPSE® II BAN® Nebulizer helped significantly reduce the number of influenza cases among frontline staff, leading to an 88% reduction in the cost of sick days by reducing the number of sick days by 60% for the facility.
Increase Safety with a Filtered Mouthpiece for the AEROECLIPSE® BAN Nebulizers
A filtered mouthpiece accessory is available for the AEROECLIPSE® BAN® Nebulizers. This high efficiency filter kit helps stop exhaled fugitive emissions and medicinal aerosols from entering the treatment environment. The low resistance filter is easy to breathe through and filters both viral and bacterial particles offering an additional layer of protection to those in the treatment area. Simply remove the mouthpiece from the AEROECLIPSE® BAN® Nebulizers and replace with the filtered mouthpiece kit available from Monaghan Medical.
AEROBIKA® OPEP and AEROECLIPSE® BAN® Nebulizer Devices: Enhancing Mucus Clearance and Airway Management
The AEROECLIPSE® BAN® Nebulizers can be used in combination with the AEROBIKA® OPEP device, potentially saving valuable time for both patients and caregivers. The ease of use and the time savings for combining therapies may decrease some of the burden of treatment with the goal of boosting patient adherence.
A radio-labeled study confirmed that therapeutic drug delivery to the lungs remains equivalent whether the nebulizer is used on its own or in combination with the AEROBIKA® OPEP device. This integrated approach saves time without compromising therapeutic results.
It is important to note that not all nebulizer and OPEP device combinations perform equally. In some cases, pairing devices can reduce aerosol delivery to the lungs by as much as 50 to 65 percent, potentially undermining treatment efficacy. Monaghan’s AEROVERSE® System is designed with intent and is reliable and consistent in its ability to maintain drug delivery while combining functions.
Enhancing Combination Technique with the Manometer Adapter
To further support effective therapy, Monaghan Medical offers the AEROBIKA® OPEP device with a manometer adapter that can be added even when used in combination with the AEROECLIPSE® BAN® Nebulizers. This addition provides valuable real-time feedback. During inhalation, a green feedback button on the AEROECLIPSE® BAN® Nebulizers may help patients slow down and focus on long, slow inhalation. During exhalation, the manometer gauge provides a goal to help users achieve the desired expiratory pressure range, helping optimizing therapy and reinforcing proper technique.
This feedback mechanism is particularly beneficial for those who are new to airway clearance therapy or even for users who maybe need a reminder about proper technique. It empowers users by helping them stay engaged throughout treatment, which may contribute to better outcomes.
VERSAPAP® Device: Positive Airway Pressure Therapy for Lung Expansion and Atelectasis
For users who would benefit from lung expansion without excessive secretions, the VERSAPAP® device helps re-expand collapsed airways by requiring less effort to take a deep breath in. The VERSAPAP® device is only offered in acute care settings and may bebeneficial post-operatively to improve surgical recovery and help reduce the development of post operative pulmonary complications caused by atelectasis. PAP therapy offers positive pressure on both inhalation and exhalation, which allows for a larger breath to enter the lungs (helping with re-expansion) and on exhalation the positive pressure stops the small air sacs from collapsing (recruiting collapsed alveoli). This therapy is effective in reducing the work of breathing as well as preventing and treating atelectasis.
Every VERSAPAP® device includes a pressure manometer to help monitor and adjust flow rates, ensuring patient comfort and keeping the treatment within therapeutic range.
Oscillations and Lung Expansion (OLE) with the VERSAPAP® and AEROBIKA® OPEP devices used in Tandem
For patients with more complex needs, the AEROBIKA® OPEP device can be used for tandem therapy with the VERSAPAP® positive airway pressure device to provide oscillations and lung expansion (OLE) therapy. This combination provides positive pressure throughout the breathing cycle and enhances therapy by promoting deeper inhalations and longer exhalations – optimizing the benefits of oscillations and airway clearance. Tandem therapy may be particularly beneficial for patients who would benefit from both airway clearance and lung re-expansion.
It is the first handheld PAP and OPEP combination to receive FDA 510(k) clearance, ensuring clinicians can offer this therapy with confidence.
The AEROVERSE® System: Integrated Respiratory Therapy from Hospital to Home
The AEROVERSE® System may be ideal for facilities seeking to increase safety and efficiency, reduce waste and costs, optimize inventory, and improve patient outcomes with no need for capital equipment and with just three core devices. The system minimizes the number of products clinicians need to learn and stock, reducing shelf space requirements and with the goal of improving safety. The slip-fit design of each component may reduce time wasted searching for additional parts or connectors. The ability to combine therapies that provide the same clinical benefit reduces time at the bedside helping healthcare teams work more efficiently.
Patients benefit from a system that adapts with them – from hospital to home – and from therapy to therapy, all without compromising effectiveness. The AEROVERSE® System reflects Monaghan Medical’s commitment to science-backed innovation, clinical excellence, and patient-centered care.
To learn how the AEROVERSE® system can improve respiratory care in your facility, contact your Monaghan Medical Territory Manager today.
